Product Information
OTEZLA 20 MG TABLET is a brand product labeled by Amgen Inc., priced at $89.9522 per EA under NDC 55513049760. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Mar 21, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Amgen Inc.NDC
55513049760
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/7/2026
Active Ingredients
APREMILASTApproval Type
New Drug (NDA)
FDA Application
NDA205437FDA Approved
3/21/2014
TE Code
AB
On Market Since
4/25/2024
Pharmacological Classes
Price Statistics
The NADAC for OTEZLA 20 MG TABLET has been published 42 times since Dec 17, 2025, and over the history we have for it it has risen 5.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $89.9522 per EA |
|---|---|
| All-time high | $89.9522 (Sep 30, 2026) |
| All-time low | $85.6687 (Dec 17, 2025) |
| 52-week high | $89.9522 |
| 52-week low | $85.6687 |
| Median price | $89.9522 |
| Average price | $89.5442 |
| Largest weekly change | +5.0% (Jan 14, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the apremilast market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
apremilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OTEZLA 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OTEZLA 20 MG TABLET, manufactured by Amgen Inc., is $89.9522 per EA (NDC 55513049760), effective Sep 30, 2026.
How has the price of OTEZLA 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for OTEZLA 20 MG TABLET has risen 5.0%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for OTEZLA 20 MG TABLET?
Since Dec 17, 2025, the NADAC for OTEZLA 20 MG TABLET has ranged from a low of $85.6687 (Dec 17, 2025) to a high of $89.9522 (Sep 30, 2026), with a median of $89.9522 per EA.
Are there cheaper alternatives to OTEZLA 20 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of OTEZLA 20 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OTEZLA 20 MG TABLET?
OTEZLA 20 MG TABLET (NDC 55513049760) is labeled by Amgen Inc., and CMS classifies it as a brand product.